| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.JACC.2010.10.018 |
| P698 | PubMed publication ID | 21310324 |
| P50 | author | Seigo Sugiyama | Q87209538 |
| Koichi Kaikita | Q96058545 | ||
| Eiichiro Yamamoto | Q113986463 | ||
| Hisao Ogawa | Q114427064 | ||
| Yasushi Matsuzawa | Q117224547 | ||
| Yasuhiro Nagayoshi | Q117250636 | ||
| Keisuke Ohba | Q117250652 | ||
| Hitoshi Sumida | Q117250653 | ||
| Toshimitsu Nozaki | Q117250654 | ||
| Junichi Matsubara | Q117250655 | ||
| Koichi Sugamura | Q117250658 | ||
| Shokei Kim-Mitsuyama | Q117250703 | ||
| P2093 | author name string | Masaaki Konishi | |
| Eiichi Akiyama | |||
| Kenji Sakamoto | |||
| P433 | issue | 7 | |
| P921 | main subject | ejection fraction | Q641303 |
| Diastolic function | Q30314111 | ||
| P304 | page(s) | 861-869 | |
| P577 | publication date | 2011-02-01 | |
| P1433 | published in | Journal of the American College of Cardiology | Q2984355 |
| P1476 | title | Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction | |
| P478 | volume | 57 |
| Q26850196 | A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation |
| Q34633271 | Albuminuria is independently associated with cardiac remodeling, abnormal right and left ventricular function, and worse outcomes in heart failure with preserved ejection fraction |
| Q50955643 | Association between suPAR and cardiac diastolic dysfunction among patients with preserved ejection fraction. |
| Q88779694 | Association of plasma pentraxin-3 levels with coronary risk factors and the lipid profile: a cross-sectional study in Japanese patients with stable angina pectoris |
| Q34150807 | Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study |
| Q92618973 | Bidirectional Relationship Between Cancer and Heart Failure: Old and New Issues in Cardio-oncology |
| Q41165768 | Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction |
| Q91640383 | Biomarkers of Inflammation in Left Ventricular Diastolic Dysfunction |
| Q26771999 | Breakthrough in heart failure with preserved ejection fraction: are we there yet? |
| Q47813656 | C-Reactive Protein Binds to Cholesterol Crystals and Co-Localizes with the Terminal Complement Complex in Human Atherosclerotic Plaques |
| Q26991726 | Cardiac biomarkers: new tools for heart failure management |
| Q38727741 | Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation |
| Q64072530 | Cross-Talk between Neurohormonal Pathways and the Immune System in Heart Failure: A Review of the Literature |
| Q64080820 | Decrease in inflammatory biomarker concentration by intervention with selenium and coenzyme Q10: a subanalysis of osteopontin, osteoprotergerin, TNFr1, TNFr2 and TWEAK |
| Q92954742 | Diagnosis and treatment of heart failure with preserved left ventricular ejection fraction |
| Q37270466 | Effect of ivabradine on endothelial function in diastolic and right heart failure patients |
| Q30367803 | Endothelial cell-derived pentraxin 3 limits the vasoreparative therapeutic potential of circulating angiogenic cells |
| Q26991985 | Exercise intolerance in heart failure with preserved ejection fraction: more than a heart problem |
| Q92845351 | H2 FPEF score for predicting future heart failure in stable outpatients with cardiovascular risk factors |
| Q37633991 | Heart failure with preserved ejection fraction in the elderly: scope of the problem |
| Q27000263 | Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies |
| Q39741385 | Heart failure: pentraxin 3—a marker of diastolic dysfunction and HF? |
| Q36463833 | Host-protective effect of circulating pentraxin 3 (PTX3) and complex formation with neutrophil extracellular traps. |
| Q34430183 | Human pentraxin 3 (PTX3) as a novel biomarker for the diagnosis of pulmonary arterial hypertension |
| Q35026270 | Incremental prognostic significance of the elevated levels of pentraxin 3 in patients with heart failure with normal left ventricular ejection fraction |
| Q35777029 | Levels of sP-selectin and hs-CRP Decrease with Dietary Intervention with Selenium and Coenzyme Q10 Combined: A Secondary Analysis of a Randomized Clinical Trial |
| Q36830914 | Long pentraxin 3: experimental and clinical relevance in cardiovascular diseases |
| Q38743215 | Management of Heart Failure with Preserved Ejection Fraction: Current Challenges and Future Directions |
| Q38100987 | New and emerging biomarkers in left ventricular systolic dysfunction--insight into dilated cardiomyopathy |
| Q40963394 | Novel plasma and imaging biomarkers in heart failure with preserved ejection fraction |
| Q82984348 | PTX3 is located at the membrane of late apoptotic macrophages and mediates the phagocytosis of macrophages |
| Q43992427 | Pentraxin 3 as a novel early biomarker for the prediction of Henoch-Schönlein purpura nephritis in children |
| Q64105040 | Pentraxin 3 in Cardiovascular Disease |
| Q35021428 | Pentraxin 3 mediates neurogenesis and angiogenesis after cerebral ischaemia. |
| Q35755280 | Pentraxin 3: a novel biomarker for inflammatory cardiovascular disease |
| Q36249503 | Pentraxin-3 Predicts Long-Term Cardiac Events in Patients with Chronic Heart Failure |
| Q42759389 | Pentraxin-3 as a marker of both the presence and the severity of metabolic syndrome |
| Q41683277 | Pentraxin-3 regulates the inflammatory activity of macrophages |
| Q38991073 | Pentraxins in the activation and regulation of innate immunity |
| Q35140370 | Plasma pentraxin 3 levels do not predict coronary events but reflect metabolic disorders in patients with coronary artery disease in the CARE trial |
| Q38105986 | Positioning of inflammatory biomarkers in the heart failure landscape |
| Q36350716 | Pressure overload-induced cardiac remodeling and dysfunction in the absence of interleukin 6 in mice |
| Q55499529 | Pro-Inflammatory Biomarkers in Stable Versus Acutely Decompensated Heart Failure With Preserved Ejection Fraction. |
| Q38134311 | Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target |
| Q36683918 | Sarcopenic obesity and the pathogenesis of exercise intolerance in heart failure with preserved ejection fraction |
| Q41741922 | Serum Pentraxin-3 Level in Patients Who Underwent Coronary Angiography and Relationship with Coronary Atherosclerosis |
| Q92592407 | Serum parathyroid hormone levels in patients with chronic right heart failure |
| Q42759835 | Serum pentraxin-3 levels are associated with the severity of metabolic syndrome |
| Q98564822 | Sex-specific microRNAs in women with diabetes and left ventricular diastolic dysfunction or HFpEF associate with microvascular injury |
| Q33577443 | Shared biomarkers between female diastolic heart failure and pre-eclampsia: a systematic review and meta-analysis |
| Q34620837 | Shenfu Injection suppresses inflammation by targeting haptoglobin and pentraxin 3 in rats with chronic ischemic heart failure |
| Q42323417 | The Effect of Intracoronary Stem Cell Injection on Markers of Leukocyte Activation in Acute Myocardial Infarction |
| Q37627769 | The acute-phase protein PTX3 is an essential mediator of glial scar formation and resolution of brain edema after ischemic injury |
| Q38806872 | The clinical significance of plasma neopterin in heart failure with preserved left ventricular ejection fraction |
| Q51129819 | The effect of candesartan on pentraxin-3 plasma levels as marker of endothelial dysfunction in patients with essential arterial hypertension. |
| Q26738957 | The inflammatory protein Pentraxin 3 in cardiovascular disease |
| Q47626900 | Update on the role of Pentraxin 3 in atherosclerosis and cardiovascular diseases |
| Q91943634 | Western Diet-Fed, Aortic-Banded Ossabaw Swine: A Preclinical Model of Cardio-Metabolic Heart Failure |
Search more.